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Abstract
The administration of granulocyte colony-stimulating factor (G-CSF) to peripheral blood
progenitor cell (PBPC) donors causes spleen length to increase, but the duration of enlargement is
not known. Eighteen healthy subjects were given 10 µg/kg of G-CSF for 5 days and a PBSC
concentrate was collected by apheresis. Ultrasound scans were used to assess craniocaudal spleen
length before and after G-CSF administration. Mean spleen length increased from a baseline length
of 10.7 ± 1.3 cm to 12.1 ± 1.2 cm on the apheresis day (p < 0.001). Ten days after apheresis, spleen
length fell to 10.5 ± 1.2 cm and did not differ from baseline levels (p = 0.57), but in 3 subjects
remained 0.5 cm greater than baseline length. Increases in spleen length in PBPC donors are
transient and reversible.
Background
Peripheral blood progenitor cell (PBPC) concentrates
donors are routinely given granulocyte colony-stimulat-
ing factor (G-CSF) to increase the concentration of circu-
lating PBPCs and hence the number of progenitors that
can be collected by apheresis. Typically 10 to 16 µg/kg of
G-CSF are given subcutaneously daily for 4 to 6 days prior
to the collection [1-3]. The administration of G-CSF to
healthy PBPC concentrates donors is very safe, but there
have been four reports of spontaneous rupture of the
spleen and splenectomy in healthy allogeneic PBPC
donors given G-CSF [4-7].
While spontaneous rupture of the spleen in PBSC donors
given G-CSF is rare, the administration of G-CSF for five
days causes spleen length to increase in almost all healthy
donors [8,9]. The increase in length is highly variable, but
the mean increase is approximately 13%. Spleen length
begins to return to baseline levels quickly, but it is not
known how long it takes to return to baseline. In a previ-
ous study of 20 PBPC donors given 10 µg/kg of G-CSF for
5 days, we found that spleen length measured four days
after the last dose of G-CSF was less than the length on the
day of apheresis but greater than baseline values [8].
Since allogeneic PBPC donors may be at risk for splenic
rupture while the spleen is enlarged, it is important to
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purpose of this study was to determine if spleen length
returns to baseline 10 days after G-CSF-mobilized PBPC




All of the subjects were in good health and were donating
G-CSF-mobilized PBPC concentrates for laboratory inves-
tigations. The donors were given 10 µg/kg of G-CSF (Fil-
grastim, Amgen, Thousand Oaks, CA) daily for 5 days,
and a PBSC concentrate was collected approximately 2
hours after the last G-CSF dose was given. PBPC concen-
trates were collected with a CS3000 blood cell separator
(Baxter Health Care Corporation, Round Lake, IL). Spleen
length was evaluated by ultrasound examination three
times: prior to the administration of the first dose of G-
CSF, on the day of apheresis, and 10 or 11 days after
apheresis. This study was approved by the Institutional
Review Board of the National Heart, Lung, and Blood
Institute, National Institutes of Health, Bethesda,
Maryland.
Spleen length assessment
Craniocaudal spleen length was assessed using ultrasound
(Acuson Aspen Advanced, Siemens Medical Solutions
Ultrasound Division, Mountain View, CA) with a sector
transducer (Acuson, 4V1, 4.0 mHz frequency, Siemens
Medical Solutions). The intra-observer error for measur-
ing spleen length using ultrasound is 4.9 mm when
healthy subjects are evaluated at separate settings [10].
Blood counts and chemistries
Complete blood counts were performed with an auto-
mated cell counter (Cell Dyne 4000, Abbott Diagnostics,
Santa Clara, CA). CD34+ cell counts were performed
using a flow cytometer (Beckman Coulter, Miami, FL).
Statistical analysis
Spleen lengths measured before and after the G-CSF
course were compared using 2-tailed paired t-tests. Spleen
length changes were also compared among males and
females and Caucasians and non-Caucasians using 2-
tailed t-tests. The percent change in spleen length was
compared with blood counts, CD34+ cell counts, and
donor age using linear regression.
Results and Discussion
The median age of the 18 healthy subjects was 34 years
old and ranged from 22 to 55 years of age. Eight of the
subjects were male, 13 of the donors were Caucasian, 3
were African American, and 2 Asian. Apheresis day spleen
length increased above baseline length in 17 of 18 donors
(Figure 1). The mean spleen length increased from a base-
line level of 10.7 ± 1.3 cm to 12.1 ± 1.2 cm on the day of
apheresis (p < 0.001). The mean increase in length was 1.4
± 0.8 cm or 13.1 ± 8.9%.
Spleen length was measured 10 or 11 days after apheresis
in all 18 subjects. The mean spleen length 10 days after
apheresis fell to 10.5 ± 1.2 cm and was less than the apher-
esis day spleen length (p < 0.001). There was no difference
between the 10-day post-apheresis and pre-G-CSF spleen
length (p = 0.57). The spleen length 10 days after apher-
esis was less than the apheresis day length in all 17 donors
whose spleen length increased. However, the spleen
length 10 days after apheresis remained more than 0.5 cm
greater than baseline spleen length in 3 subjects (Table 1).
All 3 were Caucasian and 2 were female. Their spleen
length remained 6.7%, 11.0%, and 10.5% greater than
baseline levels. Two of these subjects had relatively large
increases in spleen length of 18.3% and 26.3%, but their
spleen length fell considerably 10 days after apheresis. It
is likely that the spleen returned to baseline length in
these 2 subjects shortly after the third ultrasound was pre-
formed. The other subject's spleen increased only 12.0%
in length and 10 days after apheresis had changed little. It
is not certain when this subject's spleen returned to base-
line length.
PBPC donors with the largest increase in spleen size may
be at the greatest risk for spontaneous splenic rupture. In
order to determine if subject age, gender, race, or post-G-
CSF blood counts affected the magnitude of spleen
enlargement, we assessed the relationship between these
factors and percent change in spleen length in the 18 sub-
jects in this study and 20 subjects studied previously [14].
There was no difference in the spleen length increase
between males and females (12.3 ± 9.7% versus 14.8 ±
8.0%, p = 0.40) or between Caucasians and non-Cauca-
sians (13.5 ± 8.4% versus 13.6 ± 10.4%; p = 0.98). Spleen
length increase was not related to donor age (r = 0.13). In
addition, spleen length increase was not related to prea-
pheresis CD34+ (r = 0.04), WBC (r = 0.05), neutrophil (r
= 0.07), lymphocyte (r = -0.14), monocyte (r = -0.04), and
platelet counts (r = 0.19) or hemoglobin level (r = -0.04).
Conclusions
Healthy PBPC concentrate donors given G-CSF should be
warned that their spleens will be enlarged for a brief time
and that they may be at risk of splenic rupture. Most
donors are likely at risk for splenic rupture only during the
time of G-CSF administration and for about 10 days after
the completion of the G-CSF course. Since splenic enlarge-
ment may persist for longer periods in some donor, until
more data are available it may be worthwhile to counsel
PBPC donors to avoid activities that could lead to abdom-
inal and splenic trauma for 2 to 3 weeks after the last dose
of G-CSF.Page 2 of 4
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Spleen length changes in healthy subjects donating G-CSF-mobilized PBPC concentrates. Eighteen subjects were given 10 µg/kg 
of G-CSF for 5 days and a PBPC concentrate was collected approximately 2 hours after the last dose of G-CSF. Spleen length 
was measured by ultrasound before G-CSF was given (day 1), immediately after the PBPC concentrate collection (day 5), and 
approximately 10 or 11 days after the collection (day 15 or 16).
Table 1: Peripheral Blood Stem Cell Donors Whose Spleen Length 10 Days After Apheresis Remained More than 0.5 cm Greater than 
Baseline Length
Spleen Length (cm)
Donor Age (Yrs) Gender Race Baseline Apheresis Day 10 Days Post-Apheresis Enlargement 10 Days 
Post-Apheresis
7 23 Female Cauc 10.4 12.3 11.1 0.7
13 22 Female Cauc 10.0 11.2 11.1 1.1
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